Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study

Steven Le Gouill, Mary Callanan, Elizabeth Macintyre, MD, PhD, marie-Hélène delfau-Larue, Caroline bodet-Milin, MD, Michel Meignan, MD, PhD, Anne Moreau, MD, Alexandra Travers-Glehen, Marie-christine Béné, Corinne Haouin, MD, Remy Gressin, MD, Rene-Olivier Casasnovas, MD, Vincent Ribrag, MD, Gandhi Damaj, MD, Emmanuel Gyan, MD, PhD, Lucie Oberic, Krimo Bouabdallah, MD, Catherine Thieblemont, MD, PhD, Olivier Hermine, MD, PhD

Blood (2012) 120 (21): 152.

https://doi.org/10.1182/blood.V120.21.152.152

Published: 2012

Journal Articles

The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories

Blood (2012) 120 (21): 1399.

https://doi.org/10.1182/blood.V120.21.1399.1399

Published: 2012

Journal Articles

Higher HHV-6 Reactivation After Cord Blood Allo-SCT Is Not Related to HHV-6 Cell Receptor CD46 Expression

Patrice Chevallier, MD, Nelly Robillard, Marina Illiaquer, Julie Esbelin, Mohamad Mohty, MD PhD, Celine Bodin-Bressollette, Thierry Guillaume, MD, Veronique Stocco, MD, Fabienne Auffray, Sophie Derenne, Lucie Planche, Marie-christine Béné, Berthe-Marie Imbert-Marcille

Blood (2012) 120 (21): 1931.

https://doi.org/10.1182/blood.V120.21.1931.1931

Published: 2012

Journal Articles

Interlaboratory Validation of a 3-Tube 10-Color Antibody Flow Cytometry Panel for Diagnosis of Myelodysplastic Syndromes

Wolfgang Kern, MD, Marie-Christine Béné, PhD, Anna Porwit, MD, PhD

Blood (2012) 120 (21): 4941.

https://doi.org/10.1182/blood.V120.21.4941.4941

Published: 2012

Journal Articles

Single-Agent Dasatinib Does Not Prevent Hematological Relapse in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Complete Remission, but Persistent or Re-Appearing Molecular Minimal Residual Disease–Results of the DASA-CBF Trial From the French AML Intergroup

Blood (2011) 118 (21): 2608.

https://doi.org/10.1182/blood.V118.21.2608.2608

Published: 2011

Journal Articles

RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age

Sophie Park, Nicolas Chapuis, Franck Saint Marcoux, PharmD, PhD, Christian Recher, MD, PhD, Norbert Vey, MD, Thomas Prebet, MD, PhD, Patrice Chevallier, MD, Jean-Yves Cahn, MD, Arnaud Pigneux, MD, PhD, Bruno Lioure, Francis Witz, MD, Thierry Lamy, MD, PhD, Annabelle Merlat, Roselyne Delepine, Francois Dreyfus, Marie-christine Béné, Norbert Ifrah, Didier Bouscary, MD, PhD

Blood (2011) 118 (21): 945.

https://doi.org/10.1182/blood.V118.21.945.945

Published: 2011

Journal Articles

Minimal Residual Disease At 3 Months, Combined to the Presence of IKZF1 Deletion in B-Lineage or Absence of NOTCH1 pathway Mutation in T-Lineage, Recapitulates the Disease Risk Assessment in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia - A GRAALL Study

Blood (2011) 118 (21): 572.

https://doi.org/10.1182/blood.V118.21.572.572

Published: 2011

Journal Articles

Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial

Blood (2011) 118 (21): 410.

https://doi.org/10.1182/blood.V118.21.410.410

Published: 2011

Journal Articles

Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study

Blood (2011) 118 (21): 79.

https://doi.org/10.1182/blood.V118.21.79.79

Published: 2011

Journal Articles

High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial

Blood (2010) 116 (21): 1758.

https://doi.org/10.1182/blood.V116.21.1758.1758

Published: 2010

Journal Articles

Prognostic Value of the ‘Monosomal Karyotype’ Entity in Elderly Patients with AML: a GOELAMS Study of 186 Patients with Unfavourable Cytogenetic Abnormalities.

Blood (2009) 114 (22): 1577.

https://doi.org/10.1182/blood.V114.22.1577.1577

Published: 2009

Journal Articles

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine (F), Cyclophosphamide (C) and MabCampath (Cam) (FCCam) in Previously Untreated Patients (pts) with Advanced B-Chronic Lymphocytic Leukemia (B-CLL) : Experience On Safety and Efficacy within a Randomised Multicenter Phase III Trial of the french Cooperative Group On CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d'Etudes Des Leucémies Aigües Et Autres Maladies Du sang” (GOELAMS) : CLL2007FMP (for fit medically patients).

Stephane Lepretre, Therese Aurran, Beatrice Mahe, Bruno Cazin, Olivier Tournihlac, Hervé Maisonneuve, Olivier Casasnovas, Alain Delmer, Veronique Leblond, Bruno Royer, Brigitte Corront, Sylvie Chevret, Roselyne Delepine, Sandrine Vaudaux, Eric Van Den Neste, marie-Christine Béné, Florence Cymbalista, Pierre Feugier

Blood (2009) 114 (22): 538.

https://doi.org/10.1182/blood.V114.22.538.538

Published: 2009

Journal Articles

Diagnostic Plasma-Derived Proteomic Biomarkers of Aggressive Diffuse Large B-Cell Lymphoma: Preliminary Data Based On the 075 French GEOLAMS Multicentric and Prospective Trial.

Delphine Maucort-Boulch, Marie Arlotto, Delphine Rossille, Céline Pangault, Pascal Roy, François Berger, Anita Burgun, Marie-Christine Béné, Thierry Lamy, Noel-Jean Milpied, Thierry Fest

Blood (2009) 114 (22): 2933.

https://doi.org/10.1182/blood.V114.22.2933.2933

Published: 2009

Journal Articles

The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group

Blood (2008) 112 (11): 753.

https://doi.org/10.1182/blood.V112.11.753.753

Published: 2008

Journal Articles

A Randomised Phase II Study of Pegylated Liposomal Doxorubicine in Elderly Patients with Acute Lymphoblastic Leukemia (ALL): The GRAALL-SA1 Study.

Blood (2008) 112 (11): 918.

https://doi.org/10.1182/blood.V112.11.918.918

Published: 2008

Journal Articles

NOTCH1/FBXW7 Mutation Identifies a Large Subgroup with Favorable Outcome in Adult T-ALL: A GRAALL Study.

Blood (2008) 112 (11): 1494.

https://doi.org/10.1182/blood.V112.11.1494.1494

Published: 2008

Journal Articles

Outcome of Patients with T-Cell Lymphoblastic Leukemia or Lymphoma: The GRAALL Experience.

Stéphane Leprètre, Martine Escoffre-Barbe, Patrice Chevallier, Thibaut Leguay, Laurence Legros, Emmanuel Raffoux, Philippe Rousselot, Pascal Turlure, Norbert Vey, Denis Guyotat, Yves Chalandon, André Delannoy, Marie-Christine Béné, Elizabeth Macintyre, Norbert Ifrah, Françoise Huguet, Hervé Dombret, Agnès Buzyn

Blood (2007) 110 (11): 2818.

https://doi.org/10.1182/blood.V110.11.2818.2818

Published: 2007

Journal Articles

Prognostic Significance of CD20 Expression in Adult B-Cell Precursor Acute Lymphoblastic Leukemia.

Blood (2007) 110 (11): 2829.

https://doi.org/10.1182/blood.V110.11.2829.2829

Published: 2007

Journal Articles

Ig/TCR Monitoring of High Level MRD within the GRAALL-2003 Adult ALL Trial Has More Impact in B Than T Lineage Cases.

Kheira Beldjord, Jean-Michel Cayuela, Helene Cavé, Nathalie Grardel, Françoise Huguet, Thibaut Leguay, Veronique Lheritier, Norbert Ifrah, Herve Dombret, Marie-Christine Béné, Elizabeth MacIntyre

Blood (2006) 108 (11): 642.

https://doi.org/10.1182/blood.V108.11.642.642

Published: 2006

Journal Articles

Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial

Blood (2004) 104 (10): 3028–3037.

https://doi.org/10.1182/blood-2003-10-3560

Published: 2004

NARROW

Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study

The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories

Higher HHV-6 Reactivation After Cord Blood Allo-SCT Is Not Related to HHV-6 Cell Receptor CD46 Expression

Interlaboratory Validation of a 3-Tube 10-Color Antibody Flow Cytometry Panel for Diagnosis of Myelodysplastic Syndromes

Single-Agent Dasatinib Does Not Prevent Hematological Relapse in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Complete Remission, but Persistent or Re-Appearing Molecular Minimal Residual Disease–Results of the DASA-CBF Trial From the French AML Intergroup

RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age

Minimal Residual Disease At 3 Months, Combined to the Presence of IKZF1 Deletion in B-Lineage or Absence of NOTCH1 pathway Mutation in T-Lineage, Recapitulates the Disease Risk Assessment in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia - A GRAALL Study

Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial

Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study

High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial

Prognostic Value of the ‘Monosomal Karyotype’ Entity in Elderly Patients with AML: a GOELAMS Study of 186 Patients with Unfavourable Cytogenetic Abnormalities.

Diagnostic Plasma-Derived Proteomic Biomarkers of Aggressive Diffuse Large B-Cell Lymphoma: Preliminary Data Based On the 075 French GEOLAMS Multicentric and Prospective Trial.

The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group

A Randomised Phase II Study of Pegylated Liposomal Doxorubicine in Elderly Patients with Acute Lymphoblastic Leukemia (ALL): The GRAALL-SA1 Study.

NOTCH1/FBXW7 Mutation Identifies a Large Subgroup with Favorable Outcome in Adult T-ALL: A GRAALL Study.

Outcome of Patients with T-Cell Lymphoblastic Leukemia or Lymphoma: The GRAALL Experience.

Prognostic Significance of CD20 Expression in Adult B-Cell Precursor Acute Lymphoblastic Leukemia.

Ig/TCR Monitoring of High Level MRD within the GRAALL-2003 Adult ALL Trial Has More Impact in B Than T Lineage Cases.

Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only